UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	AL
OMB Number:	3235-0287
Estimated average burd	en
hours per response	0.5

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person *- OLUKOTUN ADEOYE Y					2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP, 26 MAIN STREET, SUITE 101					3. Date of Earliest Transaction (Month/Day/Year) 05/10/2021							Officer (give ti	tle below)		specify below)	
(Street)				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person				
CHATHAM, NJ 07928 (City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of S (Instr. 3)	•	separate line for eacl	2. Transaction Date (Month/Day/Y	Ex any (M	ecuti y Ionth	emed on Date, if /Day/Year)	Coo (Ins	Code	V Anothy.	Securities Acqui) or Disposed of sstr. 3, 4 and 5) (A) or (D) who respond	Price Own	mount of Sec ed Following saction(s) r. 3 and 4)	g Reported	O Fe D ou (I (I	wnership orm: irect (D) Indirect nstr. 4)	Beneficial Ownership
			Table					ti c cquired	his form urrently I, Dispose	are not requi valid OMB co ed of, or Benefic vertible securiti	red to res ontrol nun cially Own	pond unles nber.			· SEC	171 (5 02)
1. Title of Derivative Security (Instr. 3)	Conversion	e (Month/Day/Year)	Execution Date, if	4. Transaction Code		5. Number of		6. Date Exercisable Expiration Date (Month/Day/Year)		able and	7. Title ar of Underl Securities	Title and Amount f Underlying		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect (I)	(Instr. 4)
				Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option	\$ 1.03	05/10/2021		A		270,882		05/10	/2022(1	05/10/2031	Commo Stock	n 270,882	\$ 0	270,882	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
OLUKOTUN ADEOYE Y C/O TONIX PHARMACEUTICALS HOLDING CORP 26 MAIN STREET, SUITE 101 CHATHAM, NJ 07928	X						

Signatures

/s/ Jessica Morris, Attorney-in-Fact	05/12/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.